# References — Cognitive & Nootropic Peptide Literature — Sigma A Peptides

> The aggregated citation list for the Sigma A Peptides cognitive digest: peer-reviewed sources on Selank and Semax, with DOIs and PubMed links.

Every source cited across the two peptide pages and the comparison, gathered in one place.

## References

The list below aggregates the cited literature across both peptides on this desk — Selank and Semax. Each entry gives authors, title, journal and year, with a DOI and a PubMed link where available; a single citation is listed once and referred to by its number throughout the site. Both compounds are represented largely by Russian-origin research; where papers appear in Russian-language journals, English abstracts are available at the PubMed links listed.

## References

[1] Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923. https://pubmed.ncbi.nlm.nih.gov/30255741/
[2] Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017;2017:5091027. https://pubmed.ncbi.nlm.nih.gov/28280289/
[3] Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. https://pubmed.ncbi.nlm.nih.gov/26924987/
[4] Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences. 2008;421:241-243. https://pubmed.ncbi.nlm.nih.gov/18841804/
[5] Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(5):71-75. https://pubmed.ncbi.nlm.nih.gov/18577961/
[6] Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[7] Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315-317. https://pubmed.ncbi.nlm.nih.gov/11550013/
[8] et al. Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. Br J Pharmacol. 2025. https://pubmed.ncbi.nlm.nih.gov/40692165/
[9] Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. https://pubmed.ncbi.nlm.nih.gov/24661604/
[10] Agapova TY, et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neurosci Lett. 2007;417(2):201-5. https://pubmed.ncbi.nlm.nih.gov/17353092/
[11] Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-6. https://pubmed.ncbi.nlm.nih.gov/16635254/
[12] Romanova GA, et al. Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex. Bull Exp Biol Med. 2006;142(6):663-6. https://pubmed.ncbi.nlm.nih.gov/17603664/

---

A cross-referenced literature digest on cognitive research peptides — citations and context, not guidance and never a product for sale.